The goal of our study was twofold: (1) to determine the prevalence of the HLADQA1*05 allele among a New England IBD population, and (2) to investigate whether there exists an increased incidence of ADA development and treatment failure with anti-TNF inhibitor therapy in patients who are positive for the HLADQA1*05 allele. Here, TNF is linked to inflammatory bowel disease.